Narceine — Narcosine (Non-opioid Opium Alkaloid · Antitussive · Anti-inflammatory)

Compound	Narceine (Narcosine)
Chemical class	Alkaloid — Isoquinoline / Benzylisoquinoline (Non-opioid opium minor alkaloid)
CAS	131-28-2
Primary source	Papaver somniferum (opium, minor alkaloid ~0.1–0.5% of latex)
Key applications	Non-addictive antitussive (mild); anti-inflammatory; mucosal soothing; availability on request
Claim strength	Moderate
Typical form	Research compound; minor opium alkaloid; not widely commercially available as supplement
Buy from Herbuno	Request availability and bulk pricing →

Name origin: From Greek narkos = numbness (same root as narcotic). Narceine was isolated from opium in 1832 by Pierre-Jean Robiquet (alongside codeine in the same isolation effort). Despite its name’s narcotic connotation, narceine has no opioid receptor activity and no narcotic properties. Like noscapine and papaverine, it is a pharmacologically distinct non-opioid alkaloid from the opium poppy. Narceine is a benzylisoquinoline alkaloid — it belongs to the same structural class as papaverine but has an additional carboxyl group and a morpholinyl moiety. Traditional use: Narceine’s history of interest follows its isolation but has not resulted in significant traditional medicine adoption — it is primarily a research compound. Its original isolation from opium raised interest in antitussive potential, but noscapine proved more potent and commercially significant as the non-opioid opium antitussive. Research trajectory: Narceine has documented antitussive activity (weaker than noscapine), anti-inflammatory properties (NF-κB inhibition, COX-2 suppression), and mucosal soothing effects in in vitro and animal models. It is not commercially available as a supplement ingredient at scale but represents a scientifically interesting minor opium alkaloid with a legitimate non-addictive pharmacological profile. Commercial source: Not currently in the Herbuno catalogue. Contact Herbuno for availability assessment.

---

Evidence for Narceine Applications

Antitussive (non-opioid): Narceine suppresses the cough reflex in animal cough models, though with lower potency than noscapine. The mechanism appears to involve sigma receptor modulation (similar to noscapine) rather than opioid receptor agonism. Its non-addictive antitussive profile positions it as a reference compound in natural product antitussive research. Claim strength: Moderate (animal; limited human).

Anti-inflammatory: Narceine inhibits NF-κB and reduces COX-2 expression in macrophage and airway epithelial models. The anti-inflammatory activity complements antitussive effects — addressing both the cough reflex and the underlying airway inflammation in respiratory formulations. Claim strength: Moderate (in vitro).

Mucosal soothing: Traditional associations of opium preparations with GI mucosal soothing may partly reflect narceine’s non-opioid contribution alongside morphine’s constipating and papaverine’s antispasmodic effects. Narceine’s mucosal membrane-stabilising activity has been characterised in cell models. Claim strength: Emerging.

---

Dosage & Formulator Specification

No established human supplement dose for narceine. Research compound context: active in animal antitussive models at 10–50 mg/kg oral doses. Human equivalent extrapolation: 100–500 mg/day — but this is speculative without pharmacokinetic data. Narceine is not commercially available at supplement scale. Contact Herbuno for availability and specification if research-grade narceine is required.

---

Frequently Asked Questions — Narceine

Is narceine addictive?
No — narceine has no opioid receptor activity and no addiction potential. Despite its name (from the Greek root for narcosis) and its opium origin, narceine is pharmacologically in the same non-opioid category as papaverine and noscapine. The name reflects the historical (and ultimately inaccurate) expectation that all opium alkaloids would have narcotic properties.

How does narceine differ from noscapine as an antitussive?
Both are non-opioid opium alkaloids with antitussive properties and no addiction potential. Noscapine has significantly greater antitussive potency, more extensive research documentation, and is approved as an OTC antitussive in multiple markets. Narceine’s antitussive activity is weaker and has not been commercially developed. Structurally, noscapine is a phthalideisoquinoline; narceine is a benzylisoquinoline with a morpholine-containing side chain.

Is there any commercial production of narceine?
Narceine is available as an analytical standard from chemical suppliers at research scale but is not produced commercially for supplement or pharmaceutical applications. Extraction from opium requires separation from other major alkaloids. The commercial economics have not favoured narceine development given noscapine’s superior antitussive profile and established regulatory status in multiple markets.

What is the significance of narceine in opium alkaloid research history?
Narceine’s isolation in 1832 by Robiquet alongside codeine was significant in establishing that opium contains multiple distinct alkaloids beyond morphine. The series of alkaloid isolations from opium (morphine 1804, noscapine 1817, strychnine from nux-vomica 1818, quinine 1820, codeine and narceine 1832) established the general principle that plant drugs contain multiple distinct active principles — a foundational concept of pharmacognosy.

Related compounds: Noscapine, Papaverine, Morphine, Codeine

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery